A decade of tissue microarrays: Progress in the discovery and validation of cancer biomarkers

Journal of Clinical Oncology

Volumn 26, Issue 34, 2008, Pages 5630-5637

  Camp, Robert L ^a   Neumeister, Veronique ^a   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ANTIBODY TITER; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROTEIN EXPRESSION; REVIEW; TISSUE MICROARRAY; TUMOR CELL; TUMOR NECROSIS;

AUTOMATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MEDICAL ONCOLOGY; NEOPLASMS; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 57149117848     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.3567     Document Type: Review

References (52)

1. Wan WH, Fortuna MB, Furmanski P: A rapid and efficient method for testing immunohistochemical reactivity of monoclonal antibodies against multiple tissue samples simultaneously. J Immunol Methods 103:121-129, 1987
2. Kononen J, Bubendorf L, Kallioniemi A, et al: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847, 1998
3. LeBaron M, Crismon H, Utama F, et al: Ultrahigh density microarrays of solid samples. Nat Methods 2:511-513, 2005
4. Schoenberg Fejzo M, Slamon DJ: Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. Am J Pathol 159:1645-1650, 2001
5. Li R, Ni J, Bourne PA, et al: Cell culture block array for immunocytochemical study of protein expression in cultured cells. Appl Immunohistochem Mol Morphol 13:85-90, 2005
6. Montgomery K, Zhao S, van de Rijn M, et al: A novel method for making "tissue" microarrays from small numbers of suspension cells. Appl Immunohistochem Mol Morphol 13:80-84, 2005
7. Datta MW, Kahler A, Macias V, et al: A simple inexpensive method for the production of tissue microarrays from needle biopsy specimens: Examples with prostate cancer. Appl Immunohistochem Mol Morphol 13:96-103, 2005
8. Rimm DL, Camp RL, Charette LA, et al: Tissue microarray: A new technology for amplification of tissue resources. Cancer J 7:24-31, 2001
9. Andersen CL, Monni O, Wagner U, et al: High-throughput copy number analysis of 17q23 in 3520 tissue specimens by fluorescence in situ hybridization to tissue microarrays. Am J Pathol 160:73-79, 2002
10. Cheang MC, Treaba DO, Speers CH, et al: Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 24:5637-5644, 2006
11. Pozner-Moulis S, Cregger M, Camp RL, et al: Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model. Lab Invest 87:251-260, 2007
12. Fergenbaum JH, Garcia-Closas M, Hewitt SM, et al: Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev 13:667-672, 2004
13. Andersson AC, Strömberg S, Bäckvall H, et al: Analysis of protein expression in cell microarrays: A tool for antibody-based proteomics. J Histochem Cytochem 54:1413-1423, 2006
14. Vani K, Sompuram SR, Fitzgibbons P, et al: National HER2 proficiency test results using standardized quantitative controls: Characterization of laboratory failures. Arch Pathol Lab Med 132:211-216, 2008
15. Camp RL, Charette LA, Rimm DL: Validation of tissue microarray technology in breast carcinoma. Lab Invest 80:1943-1949, 2000
16. Rimm DL, Camp RL, Charette LA, et al: Amplification of tissue by construction of tissue microarrays. Exp Mol Pathol 70:255-264, 2001
17. DiVito KA, Charette LA, Rimm DL, et al: Long-term preservation of antigenicity on tissue microarrays. Lab Invest 84:1071-1078, 2004
18. Dhir R: Tissue microarrays: An overview. Methods Mol Biol 441:91-103, 2008
19. Torhorst J, Bucher C, Kononen J, et al: Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159:2249-2256, 2001
20. Iakovlev V, Pintilie M, Morrison A, et al: Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX. Lab Invest 87:1206-1217, 2007
21. Linderoth J, Ehinger M, Akerman M, et al: Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma. Eur J Haematol 79:146-149, 2007
22. Rubin MA, Zerkowski MP, Camp RL, et al: Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): A novel paradigm for automated and continuous biomarker measurements. Am J Pathol 164: 831-840, 2004
23. Giltnane JM, Rimm D: Technology insight: Identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol 1:104-111, 2004
24. Schnitt SJ: Estrogen receptor testing of breast cancer in current clinical practice: What's the question? J Clin Oncol 24:1797-1799, 2006
25. Rimm DL, Giltnane J, Moeder C, et al: Bimodal population or pathologist artifact? J Clin Oncol 25:2487-2488, 2007
26. Kluger HM, Siddiqui S, Angeletti C, et al: Classification of renal cell carcinoma (RCC) based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Lab Invest [epub ahead of print on July 14, 2008]
27. Rimm D: What brown cannot do for you. Nat Biotechnol 24:914-916, 2006
28. Bova GS, Parmigiani G, Epstein JI, et al: Web-based tissue microarray image data analysis: Initial validation testing through prostate cancer Gleason grading. Hum Pathol 32:417-427, 2001
29. Manley S, Mucci NR, De Marzo AM, et al: Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome: The prostate specialized program of research excellence model. Am J Pathol 159:837-843, 2001
30. Chen W, Reiss M, Foran DJ: A prototype for unsupervised analysis of tissue microarrays for cancer research and diagnostics. IEEE Trans Inf Technol Biomed 8:89-96, 2004
31. Faith D, Isaacs W, Morgan J, et al: Trefoil factor 3 overexpression in prostatic carcinoma: Prognostic importance using tissue microarrays. Prostate 61:215-227, 2004
32. Cowan JD, Rimm D, Tuck DP: Cruella: Developing a scalable tissue microarray data management system. Arch Pathol Lab Med 130:817-822, 2006
33. Makretsov NA, Huntsman DG, Nielsen TO, et al: Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 10:6143-6151, 2004
34. Au NH, Cheang M, Huntsman DG, et al: Evaluation of immunohistochemical markers in nonsmall cell lung cancer by unsupervised hierarchical clustering analysis: A tissue microarray study of 284 cases and 18 markers. J Pathol 204:101-109, 2004
35. Siddiqui SF, Pawelek J, Handerson T, et al: Coexpression of beta1,6-N-acetylglucosaminyltransferase V glycoprotein substrates defines aggressive breast cancers with poor outcome. Cancer Epidemiol Biomarkers Prev 14:2517-2523, 2005
36. Shi T, Seligson D, Belldegrun A, et al: Tumor classification by tissue microarray profiling: Random forest clustering applied to renal cell carcinoma. Mod Pathol 18:547-557, 2005
37. Dolled-Filhart M, Ryden L, Cregger M, et al: Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res 12:6459-6468, 2006
38. McCabe A, Dolled-Filhart M, Camp RL, et al: Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 97:1808-1815, 2005
39. Camp RL, Dolled-Filhart M, King BL, et al: Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res 63:1445-1448, 2003
40. Camp RL, Dolled-Filhart M, Rimm DL: X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10:7252-7259, 2004
41. Jensen KC, Turbin DA, Leung S, et al: New cutpoints to identify increased HER2 copy number: Analysis of a large, population-based cohort with long-term follow-up. Breast Cancer Res Treat [epub ahead of print on January 9, 2008]
42. Hilsenbeck SG, Clark GM, McGuire WL: Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat 22:197-206, 1992
43. Altman DG, Lausen B, Sauerbrei W, et al: Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86:829-835, 1994
44. Altman D, Royston P: The cost of dichotomising continuous variables. BMJ 332:1080, 2006
45. Royston P, Altman D, Sauerbrei W: Dichotomizing continuous predictors in multiple regression: A bad idea. Stat Med 25:127-141, 2006
46. Miller R, Siegmund D: Maximally selected chi square statistics. Biometrics 38:1011-1016, 1982
47. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007
48. Xiao Y, Gao X, Gannot G, et al: Quantitation of HER2 and telomerase biomarkers in solid tumors with IgY antibodies and nanocrystal detection. Int J Cancer 122:2178-2186, 2008
49. Dolled-Filhart M, McCabe A, Giltnane J, et al: Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 66: 5487-5494, 2006
50. Chung GG, Zerkowski MP, Ghosh S, et al: Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab Invest 87:662-669, 2007
51. Pepe MS: Evaluating technologies for classification and prediction in medicine. Stat Med 24:3687-3696, 2005
52. Persson A, Hober S, Uhlén M: A human protein atlas based on antibody proteomics. Curr Opin Mol Ther 8:185-190, 2006